G. Lopes

417 total citations
32 papers, 263 citations indexed

About

G. Lopes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, G. Lopes has authored 32 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 8 papers in Economics and Econometrics. Recurrent topics in G. Lopes's work include Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Genomics and Diagnostics (6 papers). G. Lopes is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Genomics and Diagnostics (6 papers). G. Lopes collaborates with scholars based in United States, Brazil and Spain. G. Lopes's co-authors include Tony Mok, Gilberto de Castro, Răzvan Cristescu, Andrey Loboda, Deepti Aurora-Garg, Bilal Piperdi, Jared Lunceford, Mark Ayers, Roy S. Herbst and Julie Kobie and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

G. Lopes

30 papers receiving 259 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Lopes United States	8	198	158	48	23	22	32	263
Davide Soldato Italy	10	192 1.0×	94 0.6×	56 1.2×	32 1.4×	50 2.3×	27	303
Rosario Francesco Di Stefano Italy	8	105 0.5×	153 1.0×	62 1.3×	14 0.6×	70 3.2×	25	276
Shivanshu Awasthi United States	10	142 0.7×	231 1.5×	91 1.9×	35 1.5×	79 3.6×	27	353
Valeria Stati Italy	11	182 0.9×	99 0.6×	27 0.6×	27 1.2×	61 2.8×	25	319
Noah Graham United States	9	205 1.0×	39 0.2×	39 0.8×	17 0.7×	27 1.2×	26	290
M. Guirado Spain	9	202 1.0×	254 1.6×	37 0.8×	15 0.7×	54 2.5×	24	361
Francesco Cortiula Italy	10	202 1.0×	170 1.1×	48 1.0×	32 1.4×	51 2.3×	38	324
Gianmarco Leone Italy	8	84 0.4×	101 0.6×	24 0.5×	7 0.3×	30 1.4×	20	193
Daniele Pignataro Italy	8	104 0.5×	121 0.8×	37 0.8×	5 0.2×	56 2.5×	18	232
S. Andrew Peng United States	7	184 0.9×	142 0.9×	18 0.4×	33 1.4×	20 0.9×	17	283

Countries citing papers authored by G. Lopes

Since Specialization

Citations

This map shows the geographic impact of G. Lopes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Lopes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Lopes more than expected).

Fields of papers citing papers by G. Lopes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Lopes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Lopes. The network helps show where G. Lopes may publish in the future.

Co-authorship network of co-authors of G. Lopes

This figure shows the co-authorship network connecting the top 25 collaborators of G. Lopes. A scholar is included among the top collaborators of G. Lopes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Lopes. G. Lopes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lopes, G., et al.. (2023). Econometric model of iron ore through principal component analysis and multiple linear regression. Anais da Academia Brasileira de Ciências. 95(1). e20211422–e20211422. 1 indexed citations

Mok, Tony, G. Lopes, Byoung Chul Cho, et al.. (2023). Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Annals of Oncology. 34(4). 377–388. 40 indexed citations

Lopes, G., et al.. (2023). P1.23-03 Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer. Journal of Thoracic Oncology. 18(11). S256–S256.

Gainor, Justin F., Giuseppe Curigliano, D.-W. Kim, et al.. (2021). MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 16(1). S31–S32. 2 indexed citations

Cho, Byoung Chul, Yi‐Long Wu, G. Lopes, et al.. (2021). FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC. Journal of Thoracic Oncology. 16(3). S225–S226. 20 indexed citations

Gawri, Kunal, et al.. (2021). P01.09 Improved Outcomes With Ramucirumab & Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy. Journal of Thoracic Oncology. 16(3). S239–S240. 3 indexed citations

Bravo, Gabriela, Ari M. Vanderwalde, Luis E. Raez, et al.. (2021). P76.43 Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC. Journal of Thoracic Oncology. 16(3). S605–S606. 2 indexed citations

Ejzykowicz, Flavia, Xiaohan Chen, Allison Petrilla, et al.. (2020). PCN19 PATIENT CHARACTERISTICS AND FIRST LINE TREATMENTS AMONG MEDICARE PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC). Value in Health. 23. S25–S25. 1 indexed citations

Grivas, Petros, Jeremy L. Warner, Yu Shyr, et al.. (2020). LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). Annals of Oncology. 31. S1202–S1203. 10 indexed citations

10.

Keam, Bhumsuk, Lori J. Wirth, Aaron S. Mansfield, et al.. (2020). 442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology. 31. S1413–S1414. 1 indexed citations

11.

Pino, Luís, et al.. (2020). Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers. Clinical & Translational Oncology. 23(1). 5–9. 7 indexed citations

12.

Lopes, G., et al.. (2020). PPM2 COMPREHENSIVE GENOMIC TESTING IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS OF PLASMA-BASED CIRCULATING TUMOR DNA (CTDNA) NEXT-GENERATION SEQUENCING (NGS) TO INFORM FIRST-LINE TREATMENT DECISIONS. Value in Health. 23. S326–S326. 2 indexed citations

13.

Hu, Mimi I., Vivek Subbiah, Lori J. Wirth, et al.. (2020). 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology. 31. S1084–S1084. 25 indexed citations

14.

Arora, Amit, et al.. (2019). P2.06 Lung Cancer Driver Mutations and PD-L1 Expression in US Latino Patients with Advanced Lung Cancer. Journal of Thoracic Oncology. 14(11). S1187–S1187. 1 indexed citations

15.

Herbst, Roy S., G. Lopes, Mizuho Nishio, et al.. (2019). Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Annals of Oncology. 30. v916–v917. 74 indexed citations

16.

Fundytus, Adam, Wilma M. Hopman, Nazik Hammad, et al.. (2018). Medical Oncology Workload in Canada: Infrastructure, Supports, and Delivery of Clinical Care. Current Oncology. 25(3). 206–212. 15 indexed citations

17.

Oh, Michael S., et al.. (2018). P1.04-19 Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S532–S532. 1 indexed citations

18.

Aguiar, Pedro Nazareth, et al.. (2017). P1.11-001 Economic Impact of Immune Checkpoint Inhibitor Therapy in Brazil and Strategies to Improve Access. Journal of Thoracic Oncology. 12(11). S2026–S2026. 1 indexed citations

19.

Tan, Pui San, Pedro Nazareth Aguiar, Benjamin Haaland, & G. Lopes. (2017). P2.07-055 Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer – a Network Meta-Analysis. Journal of Thoracic Oncology. 12(11). S2150–S2150. 1 indexed citations

20.

Aguiar, Pedro Nazareth, Ramon Andrade de Mello, Hakaru Tadokoro, Hani M. Babiker, & G. Lopes. (2016). Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression. Annals of Oncology. 27. vi423–vi423. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact